What's Happening?
During ESMO 2025, Michael Lahn, Chief Medical Officer at iOnctura, discussed the role of allosteric modulation in oncology. iOnctura is a clinical-stage precision oncology company focused on developing
first-in-class small molecules to treat neglected and hard-to-treat cancers. Lahn emphasized the importance of autotaxin inhibition and shared insights on the Congress's discussions. The event provided a platform for experts to explore innovative approaches in cancer treatment, highlighting the potential of allosteric modulators in improving therapeutic outcomes.
Why It's Important?
Allosteric modulation represents a promising avenue in oncology, offering new strategies to target cancer cells more effectively. By focusing on precision medicine, companies like iOnctura aim to address unmet needs in cancer treatment, potentially improving survival rates and quality of life for patients with difficult-to-treat cancers. The discussions at ESMO 2025 underscore the importance of continued research and collaboration in the field, as advancements in allosteric modulation could lead to breakthroughs in cancer therapy.
